<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39357988</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2044</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Archives of disease in childhood</Title><ISOAbbreviation>Arch Dis Child</ISOAbbreviation></Journal><ArticleTitle>Respiratory viral testing for young febrile infants presenting to emergency care: a planned secondary analysis of the Febrile Infants Diagnostic assessment and Outcome (FIDO) prospective observational cohort study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">archdischild-2024-327567</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/archdischild-2024-327567</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe the association of respiratory viral test results and the risk of invasive bacterial infection (IBI) for febrile young infants presenting to emergency care.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A planned secondary analysis within the Febrile Infants Diagnostic assessment and Outcome (FIDO) study, a prospective multicentre observational cohort study conducted across the UK and Ireland.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">35 paediatric emergency departments and assessment units across the UK and Ireland between 6 July 2022 and 31 August 2023.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Febrile infants aged 90 days and under presenting to emergency care.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">IBI (meningitis or bacteraemia) among febrile infants, undergoing respiratory viral testing for respiratory syncytial virus (RSV), influenza and SARS-CoV-2.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">1395 out of 1821 participants underwent respiratory viral testing, of those tested 339 (24.5%) tested positive for at least one of, SARS-CoV-2, RSV or influenza. A total of 45 infants (3.2%) were diagnosed with IBI. Of these, IBI occurred in 40 out of 1056 (3.8%) participants with a negative viral test and 5 out of 339 (1.5%) occurred in participants with a positive viral respiratory test (p=0.034). Infants aged 29 days and older with a positive respiratory viral test had a significantly lower rate of IBI (0.7%) compared with those with a negative test (3.2%) (p=0.015).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Young febrile infants with a positive respiratory viral test for SARS-CoV-2, RSV or influenza are at lower risk of IBI. Infants over 28 days of age with a positive viral test represent the lowest risk cohort.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT05259683.</AbstractText><CopyrightInformation>Â© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Evans</LastName><ForeName>Jordan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8873-7343</Identifier><AffiliationInfo><Affiliation>Paediatric Emergency Unit, University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff, UK jordan.evans@wales.nhs.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health and Care Research Wales, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Umana</LastName><ForeName>Etimbuk</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waterfield</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast School of Medicine Dentistry and Biomedical Sciences, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>FIDO Study Group in collaboration with PERUKI</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05259683</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arch Dis Child</MedlineTA><NlmUniqueID>0372434</NlmUniqueID><ISSNLinking>0003-9888</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Emergency Care</Keyword><Keyword MajorTopicYN="N">Infectious Disease Medicine</Keyword><Keyword MajorTopicYN="N">Paediatric Emergency Medicine</Keyword><Keyword MajorTopicYN="N">Respiratory Medicine</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Mills</LastName><ForeName>Clare</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norman-Bruce</LastName><ForeName>Hannah</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Hannah</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>McFetridge</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woolfall</LastName><ForeName>Kerry</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lynn</LastName><ForeName>Fiona</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKeeman</LastName><ForeName>Gareth</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barrett</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roland</LastName><ForeName>Damian</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyttle</LastName><ForeName>Mark D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watson</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>21</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39357988</ArticleId><ArticleId IdType="doi">10.1136/archdischild-2024-327567</ArticleId><ArticleId IdType="pii">archdischild-2024-327567</ArticleId></ArticleIdList></PubmedData></PubmedArticle>